395 related articles for article (PubMed ID: 30696304)
21. Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
Diamond B; Maclachlan K; Chung DJ; Lesokhin AM; Ola Landgren C
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101140. PubMed ID: 32139006
[TBL] [Abstract][Full Text] [Related]
22. Second malignancies in multiple myeloma; emerging patterns and future directions.
Maclachlan K; Diamond B; Maura F; Hillengass J; Turesson I; Landgren CO; Kazandjian D
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101144. PubMed ID: 32139010
[TBL] [Abstract][Full Text] [Related]
23. Canadian cost analysis comparing maintenance therapy with bortezomib versus lenalidomide for patients with multiple myeloma post autologous stem cell transplant.
LeBlanc R; Hollmann S; Tay J
J Popul Ther Clin Pharmacol; 2016; 23(1):e103-13. PubMed ID: 27337740
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
25. Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.
Richardson PG; Holstein SA; Schlossman RL; Anderson KC; Attal M; McCarthy PL
Expert Opin Pharmacother; 2017 Dec; 18(18):1975-1985. PubMed ID: 29172855
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Moreau P; Attal M; Hulin C; Arnulf B; Belhadj K; Benboubker L; Béné MC; Broijl A; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Garderet L; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Lenain P; Macro M; Mathiot C; Orsini-Piocelle F; Perrot A; Stoppa AM; van de Donk NW; Wuilleme S; Zweegman S; Kolb B; Touzeau C; Roussel M; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Fermand JP; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Zhuang S; Chiu C; Pei L; de Boer C; Smith E; Deraedt W; Kampfenkel T; Schecter J; Vermeulen J; Avet-Loiseau H; Sonneveld P
Lancet; 2019 Jul; 394(10192):29-38. PubMed ID: 31171419
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
28. Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach.
Lahoud OB; Landau H; Nguyen J; Devlin S; Lendvai N; Weltz J; Ayorinde T; Chung DJ; Lesokhin AM; Kewalramani T; Korde N; Mailankody S; Landgren O; Giralt S; Comenzo RL; Hassoun H
Leuk Lymphoma; 2022 Sep; 63(9):2126-2135. PubMed ID: 35648041
[TBL] [Abstract][Full Text] [Related]
29. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis.
Clave E; Douay C; Coman T; Busson M; Bompoint C; Moins-Teisserenc H; Glauzy S; Carmagnat M; Gorin NC; Toubert A; Garderet L
Leuk Lymphoma; 2014 Aug; 55(8):1788-95. PubMed ID: 24237448
[TBL] [Abstract][Full Text] [Related]
30. Treatment of newly diagnosed multiple myeloma in transplant-eligible patients.
Kumar S
Curr Hematol Malig Rep; 2011 Jun; 6(2):104-12. PubMed ID: 21394431
[TBL] [Abstract][Full Text] [Related]
31. Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan.
Liu Y; Tang CH; Qiu H; Siggins S; Hou HA
Sci Rep; 2021 Jan; 11(1):1112. PubMed ID: 33441901
[TBL] [Abstract][Full Text] [Related]
32. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
Durie BGM; Hoering A; Sexton R; Abidi MH; Epstein J; Rajkumar SV; Dispenzieri A; Kahanic SP; Thakuri MC; Reu FJ; Reynolds CM; Orlowski RZ; Barlogie B
Blood Cancer J; 2020 May; 10(5):53. PubMed ID: 32393732
[TBL] [Abstract][Full Text] [Related]
33. [Current Recommendations for the First-Line Therapy of Symptomatic Multiple Myeloma].
John L; Goldschmidt H; Scheid C
Dtsch Med Wochenschr; 2020 Jun; 145(12):813-819. PubMed ID: 32557483
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma.
Sidiqi MH; Aljama MA; Bin Riaz I; Dispenzieri A; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Rajkumar SV; Kumar SK; Gertz MA
Blood Cancer J; 2018 Nov; 8(11):106. PubMed ID: 30409963
[TBL] [Abstract][Full Text] [Related]
35. Developments in consolidation and maintenance strategies in post-remission multiple myeloma.
Morè S; Corvatta L; Maracci L; Costantini B; Olivieri A; Offidani M
Expert Rev Hematol; 2020 Apr; 13(4):351-362. PubMed ID: 32162982
[No Abstract] [Full Text] [Related]
36. Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy.
Mohan M; Janz S; Brazauskas R; Dwinell MB; Teng BQ; Yun G; Dong J; Pasquini MC; Giralt S; Landau H; Stadtmauer E; Krishnan A; D'Souza A
Bone Marrow Transplant; 2023 Aug; 58(8):953-955. PubMed ID: 37149674
[No Abstract] [Full Text] [Related]
37. Evolving role of stem cell transplantation in multiple myeloma.
Harousseau JL; Moreau P
Clin Lymphoma Myeloma; 2005 Sep; 6(2):89-95. PubMed ID: 16231846
[TBL] [Abstract][Full Text] [Related]
38. Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma.
Takamatsu H; Munemoto S; Murata R; Terasaki Y; Nakajima K; Nakao S
Anticancer Res; 2013 Dec; 33(12):5681-5. PubMed ID: 24324117
[TBL] [Abstract][Full Text] [Related]
39. Stem Cell Transplantation in Multiple Myeloma.
Offidani M; Gentili S; Gay F; Aghemo E; Maracci L; Corvatta L; Palumbo A
Curr Cancer Drug Targets; 2017; 17(9):769-781. PubMed ID: 27659429
[TBL] [Abstract][Full Text] [Related]
40. Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients.
Potre C; Borsi E; Potre O; Samfireag M; Costachescu D; Cerbu B; Bratosin F; Secosan C; Negrean RA
Curr Oncol; 2022 Nov; 29(11):8501-8512. PubMed ID: 36354730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
